Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [11] Real-world outcomes of a Ranibizumab biosimilar product (Ongavia) in neovascular age related macular degeneration (nAMD) patients switched from a reference Ranibizumab product (Lucentis)
    Chalkiadaki, Evangelia
    Karim, Abu
    Yeung, Ian
    Koutsocheras, Georgios
    Sim, Sing Yue
    Pal, Bishwanath
    Sivaprasad, Sobha
    Nicholson, Luke
    Hamilton, Robin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [12] Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema
    Konidaris, V. E.
    Tsaousis, K. T.
    Al-Hubeshy, Z.
    Pieri, K.
    Deane, J.
    Empeslidis, T.
    EYE, 2017, 31 (11) : 1629 - 1630
  • [13] Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema
    V E Konidaris
    K T Tsaousis
    Z Al-Hubeshy
    K Pieri
    J Deane
    T Empeslidis
    Eye, 2017, 31 : 1629 - 1630
  • [14] Retrospective analysis of the real-world utilization of ranibizumab in wAMD
    Sivaprasad, Sobha
    Tadayoni, Ramin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [15] Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data
    Guerra Veloz, M.
    Belvis Jimenez, M.
    Valdes Delgado, T.
    Castro Laria, L.
    Maldonado Perez, B.
    Benitez Roldan, A.
    Perea Amarillo, R.
    Merino Bohorquez, V.
    Calleja Hernandez, M. A.
    Caunedo Alvarez, A.
    Vilches Arenas, A.
    Arguelles-Arias, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S268 - S269
  • [16] Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
    Callizo, Josep
    Ziemssen, Focke
    Bertelmann, Thomas
    Feltgen, Nicolas
    Voegeler, Jessica
    Koch, Mirja
    Eter, Nicole
    Liakopoulos, Sandra
    Schmitz-Valckenberg, Steffen
    Spital, Georg
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 2167 - 2179
  • [17] Switching to Aflibercept in Ranibizumab Refractory Age-Related Macular Degeneration: a Real-World Experience from Sweden
    Mejaddam, Assem
    Rosso, Aldana
    Westborg, Inger
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [18] Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD
    Suarez, C. Padilla
    Webb, K.
    Persad, N.
    Sercombe, J.
    Tyler, E.
    Klimova, K.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S416 - S416
  • [19] Efficacy and safety of filgrastim biosimilar Accofil® - real-world data
    Denzlinger, C.
    Taenzer, M.
    Kahner-Groene, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 239 - 239
  • [20] Real-world safety of switching from originator to biosimilar natalizumab
    Brustad, Age Winje
    Hogestol, Einar
    Meling, Martine
    Celius, Elisabeth Gulowsen
    Berg-Hansen, Pal
    Konig, Marton
    Holterbakken, Trine Alm
    Warren, David
    Gehin, Johanna
    Bolstad, Nils
    Nygaard, Gro Owren
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1056 - 1057
12345